lilly retatrutide trial Lilly's triple agonist achieves 16.8% weight loss in phase 3 New GLP-1 obesity drug, retatrutide,

Contemporary management of obesity: a comparison of bariatric metabolic surgery and novel incretin mimetic drugs

Most GLP-1 agonists are administered safely as subcutaneous injections, meaning they are injected into the fatty layer of tissue just under the skin

Glycerol as a precursor for hepatic de novo glutathione synthesis in human liver

Researchers from the University of Southern California and the University of California San Diego evaluated a large, nationally representative electronic health records database to determine the incidence of primary open-angle glaucoma (POAG), ocular hypertension (OHT) and first-line glaucoma interventions in patients with type 2 diabetes mellitus (DM) treated with tirzepatide vs

We need to expand addiction medicine education in medical school and residency training, Leggio says

[36] Semaglutide-associated kidney injury | Clinical Kidney Journal | Oxford Academic. Accessed: Nov